ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection - Argus Press

ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection  Argus Press

LONDON--(BUSINESS WIRE)--Jul 24, 2019--. Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi ...



Comments

Popular posts from this blog

The Best Flea Treatments for Cats and Dogs

Is Citronella Safe for Dogs? A Veterinarian Provides Guidance

Everything You Need to Know About Mite and Flea Bites